Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence, as part of the institute’s single technology appraisal process, invited the manufacturer of ribociclib (Kisqali(®), Novartis) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with an aromatase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Büyükkaramikli, Nasuh C., de Groot, Saskia, Riemsma, Rob, Fayter, Debra, Armstrong, Nigel, Portegijs, Piet, Duffy, Steven, Kleijnen, Jos, Al, Maiwenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386053/
https://www.ncbi.nlm.nih.gov/pubmed/30194622
http://dx.doi.org/10.1007/s40273-018-0708-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386053/
https://www.ncbi.nlm.nih.gov/pubmed/30194622
http://dx.doi.org/10.1007/s40273-018-0708-4

Ejemplares similares